Last reviewed · How we verify

Radiation Therapy Oncology Group — Portfolio Competitive Intelligence Brief

Radiation Therapy Oncology Group pipeline: 4 marketed, 0 filed, 4 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 4 Phase 3 15 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
LHRH LHRH marketed Other
AA AA marketed Oncology
Biafine cream Biafine cream marketed
Eulexin Eulexin marketed Other
CCNU CCNU phase 3 Nitrosourea alkylating agent DNA (non-selective alkylating agent) Oncology
Anti-androgen Anti-androgen phase 3
concurrent temozolomide concurrent temozolomide phase 3 alkylating agent Oncology
Sm-153 Sm-153 phase 3 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Air Force Military Medical University, China · 2 shared drug classes
  3. Shandong Cancer Hospital and Institute · 2 shared drug classes
  4. Akeso · 1 shared drug class
  5. Associazione Volontari Pazienti Oncologici · 1 shared drug class
  6. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  7. Barts & The London NHS Trust · 1 shared drug class
  8. Alliance for Clinical Trials in Oncology · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Radiation Therapy Oncology Group:

Cite this brief

Drug Landscape (2026). Radiation Therapy Oncology Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/radiation-therapy-oncology-group. Accessed 2026-05-17.

Related